Browsing by Author Su, Rila
Showing results 1 to 1 of 1
Issue Date |
Title |
Author(s) |
1-Jun-2022 |
Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC). |
Shen, Lin;Guo, Ye;Zhang, Yanqiao;Li, Wei;Gong, Jifang;Li, Qun;Ma, Zhigang;Wang, Nanya;Su, Rila;Cai, Zhongheng;Guo, Rong;Li, Peiqi;Tse, Archie N. |